

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	4	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	17	JUN 25	CA/CAPplus and USPAT databases updated with IPC reclassification data
NEWS	18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	22	JUL 28	CA/CAPplus patent coverage enhanced
NEWS	23	JUL 28	EPFULL enhanced with additional legal status information from the epline Register
NEWS	24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	25	JUL 28	STN Viewer performance improved
NEWS	26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	27	AUG 13	CA/CAPplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	28	AUG 15	CAOLD to be discontinued on December 31, 2008

NEWS 29 AUG 15 CAplus currency for Korean patents enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:05:14 ON 22 AUG 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:05:20 ON 22 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 AUG 2008 HIGHEST RN 1042670-14-3
DICTIONARY FILE UPDATES: 21 AUG 2008 HIGHEST RN 1042670-14-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10522250.str



```

chain nodes :
9 10 11
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
1-11 3-9 9-10
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-8 6-7 7-8
exact/norm bonds :
1-2 1-5 1-11 2-3 3-4 3-9 4-5 4-6 5-8 6-7 7-8 9-10
isolated ring systems :
containing 1 :

```

G1:O,S,N

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS


```

L1 STRUCTURE UPLOADED

```

=> d L1
L1 HAS NO ANSWERS
L1 STR

```



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.46

0.67

FILE 'CAPLUS' ENTERED AT 15:05:40 ON 22 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Aug 2008 VOL 149 ISS 9

FILE LAST UPDATED: 21 Aug 2008 (20080821/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s L1 SSS full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 15:05:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 534 TO ITERATE

100.0% PROCESSED 534 ITERATIONS

315 ANSWERS

SEARCH TIME: 00.00.01

L2 315 SEA SSS FUL L1

L3 18 L2

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 18 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1146039 CAPLUS Full-text

DOCUMENT NUMBER: 147:440293

TITLE: Use of thienopyrazole derivative ABL kinase inhibitors for the treatment of resistant tumors, and screening method

INVENTOR(S): Fancelli, Daniele; Isacchi, Antonella; Modugno, Michele; Moll, Jurgen; Rusconi, Luisa; Soncini, Chiara; Lupi, Rosita

PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy

SOURCE: PCT Int. Appl., 43pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007113198	A2	20071011	WO 2007-EP53013	20070329
WO 2007113198	A3	20080320		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: EP 2006-112026 A 20060330

OTHER SOURCE(S): MARPAT 147:440293

AB The invention provides low mol. weight compds., namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compds. are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compds. of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, e.g. imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compds. capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.


IT 862555-81-5 862555-87-1 862556-93-2
862556-96-5 862556-99-8 862557-05-9
862557-17-3 862557-20-8 862557-23-1
862557-28-6 862557-30-0 862557-32-2
862557-34-4 862557-39-9 862557-41-3
862557-43-5 862557-54-8 862557-55-9
862557-58-2 862557-61-7 862557-64-0
862557-75-3 862557-79-7 862557-81-1
862557-83-3 862557-86-6 862557-88-8
862557-92-4 862558-27-8 862558-40-5
862558-44-9 862558-48-3 862558-50-7
862559-05-5 862559-07-7 862559-08-8
862559-17-9 862559-20-4 862559-21-5
862559-30-6 862559-32-8 862559-34-0
862559-59-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(thienopyrazole derivative ABL kinase inhibitors for treatment of resistant
tumors, and screening method)


RN 862555-81-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862555-87-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862556-93-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862556-96-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862556-99-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862557-05-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-17-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-20-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)




RN 862557-23-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862557-28-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-30-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-32-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-34-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[[1-methylethyl]amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-39-9 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-41-3 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-43-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)



RN 862557-54-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-55-9 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-58-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-61-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-64-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862557-75-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-79-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(dimethylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-81-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-83-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclobutylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-86-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopentylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-88-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[bis(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-92-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-27-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-40-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862558-44-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methylethyl)amino]methyl]benzoyl]amino- (CA INDEX NAME)




RN 862558-48-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-50-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862559-05-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-07-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)




RN 862559-08-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-chlorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-17-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-20-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-21-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-30-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-32-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-34-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)



RN 862559-59-9 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-(benzoylamino)-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



L3 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:85753 CAPLUS Full-text
 DOCUMENT NUMBER: 146:184454
 TITLE: Preparation of 1H-thieno[2,3-c]pyrazoles as kinase, particularly Aurora kinases and IGF-1R inhibitors for treating cancer
 INVENTOR(S): Fancelli, Daniele; Moll, Juergen; Pulici, Maurizio; Quartieri, Francesca; Bandiera, Tiziano
 PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy
 SOURCE: PCT Int. Appl., 69pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007009898	A1	20070125	WO 2006-EP64055	20060710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM EP 1904503 A1 20080402 EP 2006-764123 20060710 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR PRIORITY APPLN. INFO.: EP 2005-106602 A 20050719 WO 2006-EP64055 W 20060710 OTHER SOURCE(S): MARPAT 146:184454 GI				

- AB Title compds. I [A = hetero/aryl on which the substituent -NHZR5 is at the ortho position to the CONH linker; R1, R2 = independently H, alkyl, CONH2, etc.; or R1CR2 = cycloalkyl; R3 = H, halo, OH, CN, alkyl, di/alkylamino, alkoxy; R4 = H, halo, alkoxy, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, etc.; Z = a bond, CO, C(:O)NH; R5 = H, (un)substituted cycloalkyl, alk(en)yl, aryl, etc.; and their isomers, tautomers, carriers, metabolites, prodrugs, and pharmaceutically acceptable salts] were prepared as protein kinase, especially Aurora kinases and IGF-1R, inhibitors. I, and their pharmaceutical compns., are useful in the treatment of diseases caused by and/or associated with a dysregulated protein kinase, such as cancer and cell proliferation disorders. E.g., a multi-step synthesis starting from Et 4-cyano-5-(methylthio)thiophene-2-carboxylate was given for thienopyrazole II. II was tested as Aurora-2 kinase inhibitor (IC50 = 6 nM) and for its HCT-116 colon cancer cell antiproliferative effect (IC50 = 7 nM).
- IT 921768-48-1P, 3-[2-[[(1H-Pyrrol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-49-2P, 3-[2-[[(1H-Pyrrol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-50-5P, 3-[2-((E)-2-Cyano-3-hydroxybut-2-enoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-51-6P, 3-[2-[[(Tetrahydropyran-4-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-52-7P, 3-[2-[[(5-Methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-53-8P, 3-[2-[[(Furan-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-54-9P, 3-[2-[[(Furan-3-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-55-0P, 3-[2-[[(2-Ethyl-5-methyl-2H-pyrazol-3-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-56-1P, 3-[2-(Isobutanoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-57-2P, 3-[2-[[(2-Methyl-2H-pyrazol-3-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-58-3P, 3-[2-[[(1-Methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-59-4P, 3-[2-[[(1-Methyl-1H-pyrrol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-60-7P, 3-[2-[[(Thiazol-4-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-61-8P, 3-[2-[[(1H-Pyrrol-3-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-62-9P, 3-[2-[[(1H-Imidazol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-63-0P 921768-64-1P, 3-[2-[[(1-Methyl-1H-imidazol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-65-2P, 3-[2-[[(Phenylacetyl)amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-66-3P, 3-[2-[[(Thien-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-67-4P, 3-[2-[[(Thien-3-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-68-5P, 3-(2-Acetylaminobenzoylamino)-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-69-6P, 3-[2-


[(Tetrahydropyran-4-yl)amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-70-9P,
 3-[2-(2-Fluorobenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-71-0P,
 3-[2-[4-(4-Methylpiperazin-1-yl)benzoylamino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-72-1P, 3-[2-[4-[(Morpholin-4-yl)methyl]benzoyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-73-2P,
 3-[2-[4-[(Piperidin-1-yl)methyl]benzoyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-74-3P,
 3-[2-[4-[(Pyrrolidin-1-yl)methyl]benzoyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-75-4P,
 3-[2-(2-Methylbenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-76-5P,
 3-[2-(2-Methoxybenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-77-6P,
 3-[2-(4-Methylbenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-78-7P,
 3-[2-(4-Methoxybenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-79-8P,
 3-[2-(4-Fluorobenzoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-80-1P 921768-81-2P,
 3-(2-Acetylaminobenzoylamino)-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-82-3P,
 3-[2-((E)-2-Cyano-3-hydroxybut-2-enoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-83-4P,
 3-[2-[[(Tetrahydropyran-4-yl) carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-84-5P,
 3-[2-[[(Furan-2-yl) carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-85-6P,
 3-[2-[[(2-Ethyl-5-methyl-2H-pyrazol-3-yl) carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-86-7P 921768-87-8P,
 3-[4-(4-Methylpiperazin-1-yl)-2-[[(tetrahydropyran-4-yl) carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-88-9P,
 3-[4-(4-Methylpiperazin-1-yl)-2-[[(5-methyl-1H-pyrazol-3-yl) carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-89-0P,
 3-[2-[[(Furan-2-yl) carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-90-3P,
 3-[2-[[(2-Ethyl-5-methyl-2H-pyrazol-3-yl) carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-91-4P,
 3-[4-(4-Methylpiperazin-1-yl)-2-[[(1H-pyrrol-2-yl) carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921768-92-5P,
 3-[2-((E)-2-Cyano-3-hydroxybut-2-enoylamino)-4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-93-6P,
 3-[4-(4-Methylpiperazin-1-yl)-2-[[(tetrahydropyran-4-yl) carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-94-7P,
 3-[4-(4-Methylpiperazin-1-yl)-2-[[(5-methyl-1H-pyrazol-3-yl) carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-95-8P,
 3-[2-[[(Furan-2-yl) carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-96-9P,

3-[2-[[(2-Ethyl-5-methyl-2H-pyrazol-3-yl) carbonyl] amino]-4-(4-methylpiperazin-1-yl) benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-97-0P,
 3-[4-(4-Methylpiperazin-1-yl)-2-[[(1H-pyrrol-2-yl) carbonyl] amino] benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-98-1P,
 3-[2-[[(1H-Pyrrol-2-yl) carbonyl] amino] benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid benzylamide 921768-99-2P,
 3-[[2-[[(1H-Pyrrol-2-yl) carbonyl] amino] benzoyl] amino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid N-((R)-1-phenylethyl)amide 921769-14-4P,
 3-[2-[[(5-Methylisoxazol-4-yl) carbonyl] amino] benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921769-15-5P,
 3-[2-[[(5-Methylisoxazol-4-yl) carbonyl] amino] benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide 921769-16-6P,
 3-[2-[[(5-Methylisoxazol-4-yl) carbonyl] amino]-4-(4-methylpiperazin-1-yl) benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide 921769-17-7P,
 3-[2-[[(5-Methylisoxazol-4-yl) carbonyl] amino]-4-(4-methylpiperazin-1-yl) benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of thienopyrazoles as kinase inhibitors for treating cancer)


RN 921768-48-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[(1H-pyrrol-2-yl) carbonyl] amino] benzoyl] amino]- (CA INDEX NAME)



RN 921768-49-2 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(1H-pyrrol-2-yl) carbonyl] amino] benzoyl] amino]- (CA INDEX NAME)



RN 921768-50-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

Double bond geometry as shown.




RN 921768-51-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[(tetrahydro-2H-pyran-4-yl) carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-52-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[(5-methyl-1H-pyrazol-3-yl) carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-53-8 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(2-

furanylcarbonyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA
INDEX NAME)




RN 921768-54-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(3-furanylcarbonyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA
INDEX NAME)




RN 921768-55-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-56-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(2-methyl-1-oxopropyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX
NAME)




RN 921768-57-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[(1-methyl-1H-pyrazol-5-yl) carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-58-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[(1-methyl-1H-pyrazol-3-yl) carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-59-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[(1-methyl-1H-pyrrol-2-yl) carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-60-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(4-thiazolylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-61-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(1H-pyrrol-3-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-62-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(1H-imidazol-2-ylcarbonyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-63-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-(benzoylamino)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-64-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[[2-[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)]- (CA INDEX NAME)




RN 921768-65-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(2-phenylacetyl)amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-66-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(2-thienylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-67-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(3-thienylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-68-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-(acetylamino)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-69-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(tetrahydro-2H-pyran-4-yl)amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-70-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(2-fluorobenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-71-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-72-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(4-morpholinylmethyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-73-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(1-piperidinylmethyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-74-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-75-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(2-methylbenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-76-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(2-methoxybenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-77-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(4-methylbenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 921768-78-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(4-methoxybenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 921768-79-8 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(4-

fluorobenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-80-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[5-methyl-1H-pyrazol-3-yl]carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-81-2 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-(acetamino)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)



RN 921768-82-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[2-[[2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 921768-83-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[2-[(tetrahydro-2H-pyran-4-yl) carbonyl] amino] benzoyl] amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-84-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[2-[(2-furanylcarbonyl) amino] benzoyl] amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-85-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[2-[(1-ethyl-3-methyl-1H-pyrazol-5-yl) carbonyl] amino] benzoyl] amino]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)



RN 921768-86-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)-, hydrochloride (1:?) (CA INDEX NAME)

Double bond geometry as shown.




RN 921768-87-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)-2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-88-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)-2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-89-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 921768-90-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 921768-91-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-92-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 921768-93-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-94-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)




RN 921768-95-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 921768-96-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 921768-97-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-98-1 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(phenylmethyl)-3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)



RN 921768-99-2 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1R)-1-phenylethyl]-3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 921769-14-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 921769-15-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)



RN 921769-16-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-

methyl-1-phenylethyl)- (CA INDEX NAME)



RN 921769-17-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[5-methyl-4-isoxazolyl]carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)



IT 656235-18-6P, tert-Butyl 3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylate 921767-90-0P, 3-(2-Aminobenzoylamino)-1H-thieno[2,3-c]pyrazole-5-carboxylic acid tert-butyl ester 921767-91-1P, 3-[2-Amino-4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid tert-butyl ester 921768-04-9P, 3-[2-[[1H-Pyrrol-2-yl]carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of thienopyrazoles as kinase inhibitors for treating cancer)


RN 656235-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 921767-90-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(2-aminobenzoyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 921767-91-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[2-amino-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 921768-04-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[2-[(1H-pyrrol-2-yl)carbonyl]amino]benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:916512 CAPLUS Full-text

DOCUMENT NUMBER: 145:314984

TITLE: Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, their preparation, compositions containing them and their use as inhibitors of protein kinases

INVENTOR(S): Barberis, Claude; Carry, Jean-Christophe; Doerflinger, Gilles; Barbalat-Damour, Dominique; Clerc, Francois-Frederic; Minoux, Herve

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.

SOURCE: PCT Int. Appl., 138pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2006092510	A1	20060908	WO 2006-FR480	20060303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2882751	A1	20060908	FR 2005-2199	20050304
FR 2882751	B1	20070914		
AU 2006219805	A1	20060908	AU 2006-219805	20060303
CA 2599270	A1	20060908	CA 2006-2599270	20060303
EP 1858898	A1	20071128	EP 2006-726018	20060303
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008531663	T	20080814	JP 2007-557544	20060303
US 20080146542	A1	20080619	US 2007-846669	20070829
MX 200710753	A	20071107	MX 2007-10753	20070903
KR 2007113214	A	20071128	KR 2007-720106	20070903
IN 2007KN03327	A	20080118	IN 2007-KN3327	20070907
CN 101151268	A	20080326	CN 2006-80010837	20070929
PRIORITY APPLN. INFO.:			FR 2005-2199	A 20050304
			WO 2006-FR480	W 20060303
OTHER SOURCE(S):			CASREACT 145:314984; MARPAT 145:314984	
GI				



AB Title compds. I [R1 = independently NHCOR2, NHCONHR2, NHCOOR2; R2 = H, (un)substituted cyclo/alkyl, hetero/aryl, etc.; R3-R5 = independently H, (un)substituted alkyl, alkyl/aryl, alkyl/heteroaryl; or NR3R4 = (un)substituted heterocyclyl; etc.] were prepared as inhibitors of protein kinases, particularly Aurora 2 kinase (data) for treating cancer (no data). E.g., a 7-step synthesis starting from 3,4,5-tribromopyrazole was given for thienopyrazole II. II inhibited Aurora 1, Aurora 2, CDK2 and Tie2 with IC50 of 8 nM, 8 nM, 177 nM, and 117 nM, resp. I are useful for treating neoplasm, psoriasis, glaucoma, leukemias, inflammations, etc.

IT 909252-57-9P, N-[5-(2-Phenylhydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-61-5P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-62-6P, N-[5-(2-Cyclohexylhydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-63-7P, N-[5-[(2-Benzyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-64-8P, N-[5-[[2-(2-Ethylphenyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-65-9P, N-[5-[[2-(2-Fluorophenyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-66-0P, 4-Methoxy-N-[5-[[2-(2-methylphenyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909252-67-1P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(morpholin-4-yl)methyl]benzamide 909252-73-9P, 4-Bromo-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909252-75-1P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide 909252-78-4P, cis-4-[(3,5-Dimethylpiperazin-1-yl)methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909252-79-5P 909252-89-7P 909252-90-0P 909252-91-1P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(piperazin-1-yl)methyl]benzamide 909252-92-2P 909252-93-3P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(3-methylpiperazin-1-yl)methyl]benzamide 909252-94-4P 909252-96-6P 909252-97-7P 909252-98-8P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-3-[(4-methylpiperazin-1-yl)methyl]benzamide 909252-99-9P 909253-03-8P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(piperidin-1-yl)methyl]benzamide


909253-04-9P 909253-05-0P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(pyrrolidin-1-yl)methyl]benzamide 909253-06-1P 909253-07-2P, 4-[(Azetidin-1-yl)methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909253-08-3P, 4-[(2-Dimethylaminoethyl)(methyl)amino]methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909253-09-4P 909253-10-7P 909253-11-8P 909253-12-9P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-3-[(morpholin-4-yl)methyl]benzamide 909253-13-0P 909253-16-3P, 4-[(2-Diethylaminoethyl)amino]methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909253-17-4P 909253-18-5P, 4-[[Methyl(phenyl)amino]methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909253-20-9P, 4-[(Diisopropylamino)methyl]-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide trifluoroacetate 909253-21-0P, N-[5-(2-Benzylhydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909253-22-1P, 4-Methoxy-N-[5-[[2-(pyridin-2-yl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909253-23-2P 909253-28-7P, N-(2-Methoxymethylpyrrolidin-1-yl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxamide 909253-30-1P, N-[5-[(2-Benzyl-2-methylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-32-3P, N-(Piperidin-1-yl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxamide 909253-34-5P, N-[5-(2-Benzylhydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-36-7P, N-[5-[(2-Ethyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-38-9P, N-[5-[(2-Benzyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-40-3P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-46-9P, N-[5-[[2-(4-Chlorophenyl)-2-cyclobutylmethylhydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-52-7P, N-[5-[[2-Ethyl-2-(4-fluorophenyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-55-0P, N-[5-[[2-(4-Fluorophenyl)-2-(2-methoxyethyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-58-3P, N-[5-[[2-Ethyl-2-(o-tolyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-59-4P, N-[5-[[2-Ethyl-2-(m-tolyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-60-7P, N-[5-[[2-(4-Fluorophenyl)-2-isobutylhydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-63-0P 909253-67-4P, 6-(4-Methyl-[1,4]diazepan-1-yl)-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]nicotinamide 909253-68-5P, N-[5-(Benzylidenehydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-71-0P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[2-(morpholin-4-yl)ethoxy]benzamide 909253-74-3P, 4-(4-Methyl-[1,4]diazepan-1-yl)-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909253-75-4P 909253-76-5P 909253-77-6P, N-[5-[[2-Ethyl-2-(p-tolyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as
inhibitors of protein kinases)


RN 909252-57-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-,
2-phenylhydrazide (CA INDEX NAME)




RN 909252-61-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909252-62-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-,
2-cyclohexylhydrazide (CA INDEX NAME)



RN 909252-63-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-,
2-phenyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)



RN 909252-64-8 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-,

2-(2-ethylphenyl)hydrazide (CA INDEX NAME)




RN 909252-65-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-fluorophenyl)hydrazide (CA INDEX NAME)




RN 909252-66-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-methylphenyl)hydrazide (CA INDEX NAME)




RN 909252-67-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-morpholinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909252-73-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-bromobenzoyl)amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909252-75-1 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909252-78-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 909252-79-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide, rel- (CA INDEX NAME)


Relative stereochemistry.







RN 909252-89-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909252-90-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909252-91-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-piperazinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909252-92-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-piperazinylmethyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909252-93-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(3-methyl-1-piperazinyl)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909252-94-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(3-methyl-1-piperazinyl)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




PAGE 1-A

—Me

RN 909252-96-6 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-
 [(diethylamino)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide,
 trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 909252-95-5
 CMF C25 H28 N6 O2 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 909252-97-7 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-
 [(diethylamino)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-
 methylhydrazide (CA INDEX NAME)




RN 909252-98-8 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[3-[(4-methyl-1-

piperazinyl)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909252-99-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

Me


RN 909253-03-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-piperidinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-04-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-piperidinylmethyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909253-05-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-06-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909253-07-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-08-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[[[2-(dimethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-09-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[[[2-(dimethylamino)ethyl]methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




PAGE 1-A

PAGE 1-B




RN 909253-10-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-11-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909253-12-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[3-(4-morpholinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-13-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[3-(4-morpholinylmethyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909253-16-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909253-17-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)





RN 909253-18-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-
[(methylphenylamino)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide
(CA INDEX NAME)




RN 909253-20-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[[bis(1-
methylethyl)amino)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 909253-19-6


CMF C27 H32 N6 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 909253-21-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-,
2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909253-22-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-pyridinyl)hydrazide (CA INDEX NAME)




RN 909253-23-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




RN 909253-28-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[2-(methoxymethyl)-1-pyrrolidinyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 909253-30-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-methyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909253-32-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-1-piperidinyl- (CA INDEX NAME)




RN 909253-34-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909253-36-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-38-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-phenyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)




RN 909253-40-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-46-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-(cyclobutylmethyl)hydrazide (CA INDEX NAME)




RN 909253-52-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-(4-fluorophenyl)hydrazide (CA INDEX NAME)




RN 909253-55-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-fluorophenyl)-2-(2-methoxyethyl)hydrazide (CA INDEX NAME)




RN 909253-58-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-(2-methylphenyl)hydrazide (CA INDEX NAME)




RN 909253-59-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-(3-methylphenyl)hydrazide (CA INDEX NAME)




RN 909253-60-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-fluorophenyl)-2-(2-methylpropyl)hydrazide (CA INDEX NAME)




RN 909253-63-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(3-bromophenyl)-2-ethylhydrazide (CA INDEX NAME)




RN 909253-67-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-pyridinyl]carbonyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-68-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(phenylmethylene)hydrazide (CA INDEX NAME)




RN 909253-71-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[2-(4-morpholinyl)ethoxy]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909253-74-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)




RN 909253-75-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-(cyclobutylmethyl)hydrazide, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 909253-46-9


CMF C29 H32 Cl N7 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 909253-76-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-(4-fluorophenyl)hydrazide, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 909253-52-7


CMF C26 H28 F N7 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 909253-77-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-(4-methylphenyl)hydrazide (CA INDEX NAME)




IT 909252-70-6P, N'-Methyl-N'-phenyl-3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylic hydrazide 909252-71-7P, Ethyl 3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylate 909253-69-6P, N-[5-(Hydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases)

RN 909252-70-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)



RN 909252-71-7 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, ethyl ester (CA INDEX NAME)




RN 909253-69-6 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, hydrazide (CA INDEX NAME)




IT 909253-70-9P, Ethyl 3-[4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases)

RN 909253-70-9 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)



IT 909252-87-5P, N'-(4-Chlorophenyl)-N'-methyl-3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylic hydrazide
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases)

RN 909252-87-5 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:708185 CAPLUS Full-text
 DOCUMENT NUMBER: 145:167237
 TITLE: Preparation of heterocyclo-fused pyrazoles as protein kinase inhibitors.
 INVENTOR(S): Tonani, Roberto; Bindi, Simona; Fancelli, Daniele; Pittala', Valeria; D' Anello, Matteo
 PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy
 SOURCE: U.S. Pat. Appl. Publ., 28 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060160874	A1	20060720	US 2005-37986	20050118
PRIORITY APPLN. INFO.:			US 2005-37986	20050118
OTHER SOURCE(S):	MARPAT 145:167237			

GI




AB Title compds. [I; X NR', O, S, SO, SO2; R, R1 = H, (substituted) R', COR', CO2R', CONHR', SO2R', etc.; R' = H, (substituted) alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl; R2 = R', CH2OR', OR'], were prepared Thus, Me 3-[(4-morpholin-4-ylbenzoyl)amino]-1H-thieno[3,2-c]pyrazole-5-carboxylate (preparation from Me 5-bromo-4-nitrothiophene-2-carboxylate and morpholin-4-ylbenzoic acid given) inhibited Aurora-1 kinase with IC50 <100 nM.

IT 648412-09-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclo-fused pyrazoles as protein kinase inhibitors)

RN 648412-09-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)



Absolute stereochemistry.



L3 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:510459 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 145:8163
TITLE: Substituted 1H-thieno[2,3-c]pyrazoles, their preparation, compositions containing them and their use as inhibitors of protein kinases for treating cancer
INVENTOR(S): Carry, Jean-Christophe; Doerflinger, Gilles; Bigot, Antony; Barbalat-Damour, Dominique; Clerc, Francois
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006056697	A1	20060601	WO 2005-FR2933	20051125
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
FR 2878442	A1	20060602	FR 2004-12644	20041129
EP 1824859	A1	20070829	EP 2005-822880	20051125
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008521781	T	20080626	JP 2007-542047	20051125
US 20080058402	A1	20080306	US 2007-752612	20070523
PRIORITY APPLN. INFO.:			FR 2004-12644	A 20041129
			WO 2005-FR2933	W 20051125
OTHER SOURCE(S):	CASREACT 145:8163; MARPAT 145:8163			

GI



AB Title compds. I [R1 = independently R2, NHCOR2, CH:CH-R2, etc.; R2 = heteroaryl/aryl/heterocyclo/cyclo/alkyl, etc.; R3 = alkyl, alkyl/aryl, alkyl/heteroaryl; with the proviso that when R3 = alkyl, than R1 is not hetero/aryl or CH:CH-R2, where R2 = hetero/aryl; their racemates, enantiomers and diastereomers, and their pharmaceutical addition salts with mineral and organic acids or mineral and organic bases] were prepared as inhibitors of protein kinases, particularly Aurora 2 kinase (data) for treating cancer (no data). E.g., a 7-step synthesis starting from 3,4,5-tribromopyrazole was given for thienopyrazole II•HCl. II inhibited Aurora 2, CDK2 and Tie2 with IC50 of < 50 nM, < 500 nM and < 500 nM, resp.


IT 888485-00-5P, 5-[(N-Phenoxyamino)carbonyl]-3-[[(thien-2-yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole hydrochloride
888485-03-8P, 5-[(N-Phenoxyamino)carbonyl]-3-[[(thien-2-yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 1H-thieno[2,3-c]pyrazoles as inhibitors of protein kinases and their use for treating cancer)

RN 888485-00-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-phenoxy-3-[(2-thienylcarbonyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 888485-03-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-phenoxy-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1104610 CAPLUS Full-text
 DOCUMENT NUMBER: 145:249062
 TITLE: Synthesis, reactions and antimicrobial activity of
 2-amino-4-(8-quinolinol-5-yl)-1-(p-tolyl)-pyrrole-3-
 carbonitrile
 AUTHOR(S): Abdel-Mohsen, Shawkat A.
 CORPORATE SOURCE: Chemistry Department, Faculty of Science, Assiut
 University, Assiut, 71516, Egypt
 SOURCE: Bulletin of the Korean Chemical Society (2005), 26(5),
 719-728
 CODEN: BKCSDE; ISSN: 0253-2964
 PUBLISHER: Korean Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 145:249062
 GI



AB A novel 2-amino-4-(8-quinolinol-5-yl)-1-(p-tolyl)-pyrrole-3-carbonitrile (I) was obtained by the reaction of 2-[2-bromo-1-(8-hydroxyquinolin-5-yl)-ethylidene]-malononitrile with p-toluidine. The new synthon I could be annulated to the corresponding pyrrolo[2,3-d]pyrimidines, triazolo[1,5-c]pyrrolo[3,2-e]pyrimidines, pyrrolo[2,3-c]pyrazoles, pyrrolo[1,2-a]pyrrolo[3,2-e]pyrimidine and imidazo[1,2-c]pyrrolo[3,2-e]pyrimidine via the reactions with some reagents such as acetic anhydride, formamide, tri-Et orthoformate, hydrazine hydrate, hydroxylamine, ethylenediamine, carbon disulfide and phosphorus oxychloride. Chemical and spectroscopic data for the

structures of these compds. were presented. The antifungal and antibacterial activity of the newly synthesized compds. were evaluated.


IT 906450-63-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation, antifungal and antibacterial activity of (pyrrolo)pyrazoles via condensation of amino(cyano)tolyl(quinolinyl)pyrrole with hydroxylamine followed by heterocyclization with appropriate reagents)

RN 906450-63-3 CAPLUS

CN 8-Quinolinol, 5-[3-amino-1,6-dihydro-6-(4-methylphenyl)pyrrolo[2,3-c]pyrazol-4-yl]- (CA INDEX NAME)




IT 906450-67-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, antifungal and antibacterial activity of (pyrrolo)pyrazoles via condensation of amino(cyano)tolyl(quinolinyl)pyrrole with hydroxylamine followed by heterocyclization with appropriate reagents)

RN 906450-67-7 CAPLUS

CN Thiourea, N-[1,6-dihydro-4-(8-hydroxy-5-quinolinyl)-6-(4-methylphenyl)pyrrolo[2,3-c]pyrazol-3-yl]-N'-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:823564 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:229842

TITLE: Preparation of thieno[2,3-c]pyrazole derivatives as protein kinase inhibitors

INVENTOR(S): Fancelli, Daniele; Bindi, Simona; Varasi, Mario; Vianello, Paola; Vioglio, Sergio; Tesei, Dania

PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074922	A1	20050818	WO 2005-EP1021	20050202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005210114	A1	20050818	AU 2005-210114	20050202
CA 2555262	A1	20050818	CA 2005-2555262	20050202
EP 1711177	A1	20061018	EP 2005-701307	20050202
EP 1711177	B1	20080528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1946395	A	20070411	CN 2005-80005922	20050202
BR 2005007375	A	20070710	BR 2005-7375	20050202
JP 2007520513	T	20070726	JP 2006-551790	20050202
AT 396724	T	20080615	AT 2005-701307	20050202
US 20050187209	A1	20050825	US 2005-50360	20050203
IN 2006DN04402	A	20070810	IN 2006-DN4402	20060731
MX 2006PA08787	A	20070119	MX 2006-PA8787	20060802
NO 2006003768	A	20061102	NO 2006-3768	20060823
PRIORITY APPLN. INFO.:			US 2004-541452P	P 20040203
			WO 2005-EP1021	W 20050202
OTHER SOURCE(S):	MARPAT 143:229842			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = (un)substituted aryl or heteroaryl; R1 and R2 independently = H, alkyl, CONH2, etc. or together may form cycloalkyl ring with provisions; R3 = H, halo, OH, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase inhibitors. Thus, e.g., II was prepared by amination of 1-(ethoxycarbonyl)-3-[(4- morpholin-4-ylbenzoyl)amino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid hydrochloride (preparation given) with cumylamine and subsequent deprotection. The inhibitory activity of I towards Aurora-2 kinase was evaluated utilizing a scintillation assay and it was revealed that selected compds. of the invention displayed IC50 values below 20 nM. I as protein kinase inhibitor should prove useful in the treatment of cancer. Pharmaceutical compns. comprising I are disclosed.

IT 648412-09-3P 836633-13-7P 862555-81-5P
862555-87-1P 862555-94-0P 862555-99-5P
862556-05-6P 862556-11-4P 862556-16-9P
862556-21-6P 862556-27-2P 862556-33-0P

862556-38-5P 862556-43-2P 862556-47-6P
 862556-52-3P 862556-57-8P 862556-67-0P
 862556-71-6P 862556-75-0P 862556-78-3P
 862556-81-8P 862556-84-1P 862556-87-4P
 862556-90-9P 862556-93-2P 862556-96-5P
 862556-99-8P 862557-02-6P 862557-05-9P
 862557-08-2P 862557-11-7P 862557-14-0P
 862557-17-3P 862557-20-8P 862557-23-1P
 862557-28-6P 862557-30-0P 862557-32-2P
 862557-34-4P 862557-37-7P 862557-39-9P
 862557-41-3P 862557-43-5P 862557-45-7P
 862557-47-9P 862557-49-1P 862557-51-5P
 862557-53-7P 862557-54-8P 862557-55-9P
 862557-58-2P 862557-61-7P 862557-64-0P
 862557-67-3P 862557-69-5P 862557-71-9P
 862557-73-1P 862557-75-3P 862557-77-5P
 862557-79-7P 862557-81-1P 862557-83-3P
 862557-85-5P 862557-86-6P 862557-88-8P
 862557-90-2P 862557-92-4P 862557-94-6P
 862557-95-7P 862557-96-8P 862557-98-0P
 862558-00-7P 862558-01-8P 862558-03-0P
 862558-05-2P 862558-07-4P 862558-09-6P
 862558-11-0P 862558-13-2P 862558-15-4P
 862558-17-6P 862558-19-8P 862558-21-2P
 862558-23-4P 862558-27-8P 862558-30-3P
 862558-32-5P 862558-34-7P 862558-36-9P
 862558-38-1P 862558-40-5P 862558-42-7P
 862558-44-9P 862558-46-1P 862558-48-3P
 862558-50-7P 862558-52-9P 862558-54-1P
 862558-56-3P 862558-58-5P 862558-60-9P
 862558-63-2P 862558-65-4P 862558-67-6P
 862558-69-8P 862558-71-2P 862558-73-4P
 862558-75-6P 862558-77-8P 862558-79-0P
 862558-81-4P 862558-83-6P 862558-85-8P
 862558-87-0P 862558-89-2P 862558-91-6P
 862558-93-8P 862558-95-0P 862558-97-2P
 862558-99-4P 862559-00-0P 862559-01-1P
 862559-02-2P 862559-03-3P 862559-04-4P
 862559-05-5P 862559-06-6P 862559-07-7P
 862559-08-8P 862559-09-9P 862559-10-2P
 862559-11-3P 862559-12-4P 862559-13-5P
 862559-15-7P 862559-17-9P 862559-19-1P
 862559-20-4P 862559-21-5P 862559-23-7P
 862559-24-8P 862559-26-0P 862559-28-2P
 862559-29-3P 862559-30-6P 862559-32-8P
 862559-34-0P 862559-36-2P 862559-38-4P
 862559-40-8P 862559-42-0P 862559-44-2P
 862559-46-4P 862559-48-6P 862559-50-0P
 862559-52-2P 862559-53-3P 862559-54-4P
 862559-55-5P 862559-57-7P 862559-59-9P
 862559-60-2P 862559-61-3P 862564-01-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)

RN 648412-09-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-
 piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 836633-13-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)




RN 862555-81-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)



RN 862555-87-1 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 862555-94-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862555-99-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862556-05-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862556-11-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862556-16-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 862556-21-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 862556-27-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862556-33-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862556-38-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-[(1R)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862556-43-2 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862556-47-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[(4-fluorobenzoyl)amino]- (CA INDEX NAME)



RN 862556-52-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)



RN 862556-57-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862556-67-0 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 862556-71-6 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-phenylcyclopropyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



RN 862556-75-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862556-78-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1R)-1-phenylpropyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862556-81-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]- (CA INDEX NAME)




RN 862556-84-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862556-87-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(2-furanylcarbonyl)amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862556-90-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(2-furanylcarbonyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862556-93-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862556-96-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862556-99-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862557-02-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 862557-05-9 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)



RN 862557-08-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862557-11-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862557-14-0 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862557-17-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-20-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)




RN 862557-23-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862557-28-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-30-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-32-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-34-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[1-methylethyl)amino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-37-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-39-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-41-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-43-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-45-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[[5-[[1-methyl-1-phenylethyl]amino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]amino]carbonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862557-47-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(4-fluoro-1-piperidinyl)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-49-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1-piperazinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-51-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1H-imidazol-1-ylmethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-53-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(3-thiazolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-54-8 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-55-9 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-58-2 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)



RN 862557-61-7 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-64-0 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862557-67-3 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-

azetidinylmethyl)benzoyl]amino]-N-[1-(3-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862557-69-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(4-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862557-71-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[4-(1,1-dimethylethyl)-1-piperazinyl]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-73-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-75-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-77-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(2-phenylacetyl)amino]- (CA INDEX NAME)




RN 862557-79-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(dimethylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-81-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-83-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclobutylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-85-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[methyl(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-86-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopentylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-88-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[bis(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-90-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(aminomethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862557-92-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-94-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-95-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-96-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862557-98-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-00-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-01-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-03-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(2-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862558-05-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(3-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862558-07-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinemethyl)benzoyl]amino]-N-[1-(4-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862558-09-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinymethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-11-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinymethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-13-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinymethyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-15-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)



RN 862558-17-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




PAGE 1-A

Me

PAGE 1-B

RN 862558-19-8 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




PAGE 1-A

—Me

RN 862558-21-2 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862558-23-4 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)




—Me

RN 862558-27-8 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-30-3 CAPLUS

RN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-32-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-34-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-36-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-38-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)




RN 862558-40-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862558-42-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-[1-(2-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862558-44-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[[[(1-methylethyl)amino]methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862558-46-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-[[[(1-methylethyl)amino]methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862558-48-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-50-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862558-52-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-[(1H-pyrazol-1-yl)methyl]benzoyl]amino]- (CA INDEX NAME)




RN 862558-54-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-methoxybenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-56-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(3-methoxybenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-58-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(2-methoxybenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-60-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[3-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-63-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(dimethylamino)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-65-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(3-furanylcarbonyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-67-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(3-thienylcarbonyl)amino]- (CA INDEX NAME)




RN 862558-69-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[(1-methyl-1H-pyrrol-3-yl)carbonyl]amino]- (CA INDEX NAME)




RN 862558-71-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[(1-methyl-1H-pyrazol-3-yl)carbonyl]amino]- (CA INDEX NAME)




RN 862558-73-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]- (CA INDEX NAME)




RN 862558-75-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(2-pyridinylcarbonyl)amino]- (CA INDEX NAME)




RN 862558-77-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(3-pyridinylcarbonyl)amino]- (CA INDEX NAME)




RN 862558-79-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(4-pyridinylcarbonyl)amino]- (CA INDEX NAME)




RN 862558-81-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-chlorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862558-83-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(4-phenoxybenzoyl)amino]- (CA INDEX NAME)




RN 862558-85-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-87-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-89-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-91-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-93-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862558-95-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)




RN 862558-97-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-phenylcyclopentyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)




RN 862558-99-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



RN 862559-00-0 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



RN 862559-01-1 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]-3-[[4-(trifluoromethoxy)benzoyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862559-02-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[2-(dimethylamino)ethoxy]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)



RN 862559-03-3 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[2-(dimethylamino)ethoxy]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 862559-04-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-[(1S)-1-phenyl-2-(1-piperidinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 862559-05-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-06-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1S)-1-phenyl-2-(1-piperidinyl)ethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 862559-07-7 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)




RN 862559-08-8 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-chlorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-09-9 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-chlorophenyl)-1-methylethyl]-3-[(4-fluorobenzoyl)amino]- (CA INDEX NAME)



RN 862559-10-2 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-methoxybenzoyl)amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)




RN 862559-11-3 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-phenylcyclopropyl)-3-[[4-(trifluoromethoxy)benzoyl]amino]- (CA INDEX NAME)



RN 862559-12-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[[6-(4-morpholinyl)-3-pyridinyl]carbonyl]amino]- (CA INDEX NAME)



RN 862559-13-5 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1S)-1-methyl-2-(4-morpholinyl)-1-phenylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 862559-15-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-methyl-1-(4-pyridinyl)ethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)



RN 862559-17-9 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methyl-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-19-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-20-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-21-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-23-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(methylsulfonyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-24-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1,1-dioxido-4-thiomorpholinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862559-26-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-methyl-1-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-28-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[1-methyl-1-[3-(1-pyrrolidinyl)phenyl]ethyl]- (CA INDEX NAME)




RN 862559-29-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-methyl-1-[3-(methylsulfonyl)phenyl]ethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-30-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-32-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-34-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)




RN 862559-36-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[2-thienylcarbonyl]amino]- (CA INDEX NAME)




RN 862559-38-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)




RN 862559-40-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)




RN 862559-42-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)




RN 862559-44-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[(2-furanylcarbonyl)amino]- (CA INDEX NAME)




RN 862559-46-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[(2-furanylcarbonyl)amino]- (CA INDEX NAME)




RN 862559-48-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[(2-furanylcarbonyl)amino]- (CA INDEX NAME)




RN 862559-50-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(2-furanylcarbonyl)amino]-N-[1-(2-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)




RN 862559-52-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[1-methyl-1H-pyrazol-5-yl]carbonyl]amino]- (CA INDEX NAME)




RN 862559-53-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[1-methyl-1H-pyrazol-5-yl]carbonyl]amino- (CA INDEX NAME)



RN 862559-54-4 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[1-methyl-1H-pyrazol-5-yl]carbonyl]amino- (CA INDEX NAME)



RN 862559-55-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862559-57-7 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862559-59-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-(benzoylamino)-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862559-60-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(3-fluorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 862559-61-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(2-fluorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)



RN 862564-01-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)



PAGE 1-A

Me

PAGE 1-B


IT 656235-18-6P, tert-Butyl 3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylate 862559-71-5P 862559-73-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)


RN 656235-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 862559-71-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 862559-73-7 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:99176 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 142:198080
 TITLE: Preparation of substituted thieno[2,3-c]pyrazoles and their use as medicinal products for cancer and neurodegenerative diseases
 INVENTOR(S): Bigot, Antony; Clerc, Francois; Doerflinger, Gilles; Mignani, Serge; Minoux, Herve
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
 SOURCE: U.S. Pat. Appl. Publ., 15 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050026984	A1	20050203	US 2004-900549	20040728
PRIORITY APPLN. INFO.:			FR 2003-9284	A 20030729
			US 2003-500614P	P 20030905
OTHER SOURCE(S):			CASREACT 142:198080; MARPAT 142:198080	
GI				




AB The present invention relates in particular to novel chemical compds., particularly novel substituted thieno[2,3-c]pyrazoles I [R1 = XY; X = ; Y = (un)substituted; R2 = XY, ; R = H, alkyl; n = 0 - 2; a = 1, 2; all above are optionally substituted with alkyl, aryl, amino or alkoxy; with the proviso that when R2 = R1, then X ≠ NHCO, NHSO2], to the compns. containing them and to their use as medicinal products for treating cancers and also neurodegenerative diseases. Thus, 3-phenyl-1H-thieno[2,3- c]pyrazole-5-carboxylic acid N-benzyl-N-methylamide [I; R1 = Ph, R2 = CONMeCH2Ph] was prepared from 1-benzyl-5-chloro-3-phenylpyrazole-4- carboxaldehyde via cyclocondensation with HSCH2CO2Et, chlorination with SOCl2 and amidation with PhCH2NHMe. The protein kinase inhibitory activity of I was tested against FAK, KDR, Aurora 2, Src and Tie2 (Ki = 100 - 5000 nM).

IT 836633-13-7P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of thieno[2,3-c]pyrazole derivs. for use in treatment of cancer and neurodegenerative diseases)

RN 836633-13-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



L3 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1001062 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:113983

TITLE: Mononuclear heterocyclic rearrangement: Synthesis of [5:5] bicyclic [c]-fused 3-aminopyrazoles via the N-N bond formation strategy

AUTHOR(S): Berry, David A.; Chien, Tun-Cheng; Townsend, Leroy B.

CORPORATE SOURCE: Department of Medicinal Chemistry, College of Pharmacy, The University of Michigan, Ann Arbor, MI, 48109-1065, USA

SOURCE: Heterocycles (2004), 63(11), 2475-2494
 CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:113983


AB The formation of [5:5] bicyclic heterocyclic ring systems containing [c]pyrazoles, i.e. imidazo[4,5-c]pyrazole, pyrazolo[3,4-c]pyrazole, pyrrolo[2,3-c]pyrazole, and pyrazolo[3,4-d][1,2,3]triazole, was accomplished by mononuclear heterocyclic rearrangement (MHR). The core pyrazole ring was formed based on a N-N bond formation strategy. The ring transformation of 5-substituted 3-(2-aminoaryl)-1,2,4-oxadiazoles, under thermal conditions to the corresponding [5:5] bicyclic [c]-fused 3-aminopyrazole ring systems was promoted by sodium hydride in DMF or DMSO. The ring transformation by MHR has provided a practical and general synthetic method for the derivs. of 3-aminoimidazo[4,5-c]pyrazole, 3-aminopyrrolo[2,3-c]pyrazole, and 6-aminopyrazolo[3,4-d][1,2,3]triazole.

IT 821004-47-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of N-[cyano(pyrrolo[2,3-c]pyrazolyl)]benzamide using [amino(iminomethyl)pyrrolecarboxamide as synthetic intermediate]

RN 821004-47-1 CAPLUS

CN Benzamide, N-[5-cyano-1,6-dihydro-6-(phenylmethyl)pyrrolo[2,3-c]pyrazol-3-yl]-4-nitro- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:120860 CAPLUS Full-text

DOCUMENT NUMBER: 140:163864

TITLE: Preparation of condensed heterocyclic pyrazole derivatives as protein kinase inhibitors

INVENTOR(S): Tonani, Roberto; Bindi, Simona; Fancelli, Daniele; Pittala, Valeria; Varasi, Mario

PATENT ASSIGNEE(S): Pharmacia Italia S.P.A, Italy

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013146	A1	20040212	WO 2003-EP7531	20030711
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,			

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG



CA 2493680	A1	20040212	CA 2003-2493680	20030711
AU 2003250040	A1	20040223	AU 2003-250040	20030711
EP 1530573	A1	20050518	EP 2003-766152	20030711
EP 1530573	B1	20080319		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003012961	A	20050614	BR 2003-12961	20030711
JP 2005537288	T	20051208	JP 2004-525180	20030711
AT 389658	T	20080415	AT 2003-766152	20030711
MX 2005PA00946	A	20050516	MX 2005-PA946	20050124
US 20060122249	A1	20060608	US 2005-522250	20050919

PRIORITY APPLN. INFO.: US 2002-398121P P 20020725
WO 2003-EP7531 W 20030711

OTHER SOURCE(S): MARPAT 140:163864
GI




AB The title compds. I [wherein X = O, S, SO, SO2, or NR'; R and R1 = independently H, (un)substituted R', COR', CO2R', CONHR', CONR'R'', SO2R', SO2NHR', or SO2NR'R''; R' and R'' = independently H, (un)substituted alkyl, heterocyclyl, aryl, or aralkyl; R2 = (un)substituted R', CH2OR', or OR'] or pharmaceutically acceptable salts thereof are prepared. For example, the compound II was prepared in a five-step synthesis starting from Et 4-cyano-5-(methylthio)thiophene-2-carboxylate. I can be used as protein kinase inhibitors, and are useful for the treatment of cancer (no data).

IT 656235-18-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of condensed heterocyclic pyrazole derivs. as protein kinase inhibitors)


RN 656235-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)



L3 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:60516 CAPLUS Full-text
 DOCUMENT NUMBER: 140:111412
 TITLE: Preparation of heterobicyclic pyrazole derivatives as
 kinase inhibitors
 INVENTOR(S): Tonani, Roberto; Bindi, Simona; Fancelli, Daniele;
 Pittala, Valeria; Danello, Matteo
 PATENT ASSIGNEE(S): Pharmacia Italia S.P.A., Italy
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007504	A1	20040122	WO 2003-EP7529	20030711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492673	A1	20040122	CA 2003-2492673	20030711
AU 2003254337	A1	20040202	AU 2003-254337	20030711
BR 2003012722	A	20050510	BR 2003-12722	20030711
EP 1534716	A1	20050601	EP 2003-763818	20030711
EP 1534716	B1	20080423		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501191	T	20060112	JP 2004-520596	20030711
AT 393159	T	20080515	AT 2003-763818	20030711
TW 284645	B	20070801	TW 2003-92119120	20030714
MX 2005PA00629	A	20050425	MX 2005-PA629	20050114
PRIORITY APPLN. INFO.:			US 2002-396174P	P 20020717
			WO 2003-EP7529	W 20030711
OTHER SOURCE(S):		MARPAT 140:111412		
GI				



AB The title compds. [I; X = NR', O, S, SO, SO₂; R, R₁ = H, R', COR', CO₂R', CONHR', CONR'R'', SO₂R', SO₂NHR', SO₂NR'R'' (wherein R', R'' = H, alkyl, aryl, etc.); R₂ = R', CH₂OR', OR'] which may be useful, in therapy, in the treatment

of diseases associated with a disregulated protein kinase activity, like cancer, were prepared E.g., a multi-step synthesis of Me 3-[(4-morpholin-4-ylbenzoyl)amino]-1H-thieno[3,2-c]pyrazole-5-carboxylate which showed IC50 of <100 nM, <1000nM, and of <500 nM against Aurora-2, cdc7, and PAK-4, resp., was given. The pharmaceutical compns. comprising the compds. I are disclosed.

IT 648412-09-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterobicyclic pyrazole derivs. as kinase inhibitors)

RN 648412-09-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:402031 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 129:122635

ORIGINAL REFERENCE NO.: 129:25129a,25132a

TITLE: The reaction of phenacilmalononitrile with hydrazines: synthesis of new pyridazinones and pyrazolo[1,5-a]pyrimidines

AUTHOR(S): Elnagdi, Mohamed Hilmy; El-Ghamry, Ibrahim; Kandeel, Ezz; Abdel Rahman, A. H.; Al-Naggar, Abdul Aziz; Amer, Samir; Riad, Mohamed

CORPORATE SOURCE: Department of Chemistry, Faculty of Science, University of Kuwait, Safat, 13060, Kuwait

SOURCE: Gazzetta Chimica Italiana (1997), 127(12), 791-794
CODEN: GCITA9; ISSN: 0016-5603

PUBLISHER: Societa Chimica Italiana

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:122635


AB The reaction of phenacilmalononitrile with hydrazine hydrate affords a mixture of 3,5-diamino-4-phenacilpyrazole (I), and 6-oxo-3-phenyl-1,4,5,6-tetrahydropyridazine-5-carbonitrile. The reaction of I with a variety of reagents, that enabled the synthesis of some new pyrazolo[1,5-a]pyrimidine derivs., is described.

IT 210347-43-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of pyridazinones and pyrazolo[1,5-a]pyrimidines)

RN 210347-43-6 CAPLUS
CN 1H-Furo[2,3-c]pyrazol-3-amine, 5-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:239968 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 129:4623

ORIGINAL REFERENCE NO.: 129:1109a,1112a

TITLE: Synthesis of thieno-heterocycles from substituted 5-(methylthio)thiophene-4-carbonitriles

AUTHOR(S): Briel, D.

CORPORATE SOURCE: Inst. Pharmazie, Fak. Biowissenschaften, Pharmazie, Psychologie, Univ. Leipzig, Leipzig, D-04103, Germany

SOURCE: Pharmazie (1998), 53(4), 227-231

CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 129:4623


AB 5-(Methylthio)-4-thiophenenitriles were used as C3-synthons for the synthesis of thienodipyrimidines, thienopyrimidines, thienopyridines, thienopyrazoles, and pyrazolothienopyrimidines. The thienopyrazoles and pyrazolothienopyrimidines were screened for antiulcer activity.

IT 207452-82-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiulcer activity)

RN 207452-82-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 4-(acetylamino)-3-amino-, methyl ester (CA INDEX NAME)



L3 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:619483 CAPLUS [Full-text](#)


DOCUMENT NUMBER: 127:331458

ORIGINAL REFERENCE NO.: 127:65097a,65100a

TITLE: Syntheses with heterocyclic β -enamino nitriles.

An expeditious synthetic approach to polyfunctionally substituted 5-phenyl-sulfonylthiophenes and their fused derivatives

AUTHOR(S): Sherif, S. M.; Hussein, A. M.
CORPORATE SOURCE: Faculty Science, Cairo University, Giza, Egypt
SOURCE: Monatshefte fuer Chemie (1997), 128(6/7), 687-696
CODEN: MOCMB7; ISSN: 0026-9247
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:331458
GI




AB PhSO₂CH₂COC₆H₄-4-R (R = H, Br) reacts with a mixture of elemental S and CH₂(CN)₂ to yield the corresponding thiophenecarbonitriles I. Compound I (R = H) could be annelated to the corresponding thieno[2,3-d]pyrimidine and thieno[2,3-c]pyrazole (II) upon reaction with the N nucleophiles NH₂CN and NH₂OH.HCl, resp. The applicability and synthetic potency of II to develop a facile convenient route to polyfunctional thieno[2',3':3,4]pyrazolo[1,5-a]pyrimidines is reported.

IT 197861-67-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (phenylsulfonyl)thiophenes as heterocyclic enamino nitriles and their fused derivs.)


RN 197861-67-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazol-3-amine, 4-phenyl-5-(phenylsulfonyl)- (CA INDEX NAME)




L3 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:962283 CAPLUS Full-text
DOCUMENT NUMBER: 124:176031
ORIGINAL REFERENCE NO.: 124:32643a, 32646a
TITLE: Thieno[2',3':3,4]pyrazolo[1,5-a]pyrimidines and -triazines: synthesis of the novel ring systems
AUTHOR(S): Briel, D.

CORPORATE SOURCE: Institut Pharmazie, Universitaet Leipzig, Germany
 SOURCE: Pharmazie (1995), 50(10), 675-8
 CODEN: PHARAT; ISSN: 0031-7144
 PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 124:176031
 GI



I



II


AB The novel tricyclic ring systems I (R = CO₂Me; R₁ = Me, 2-HOC₆H₄, Ph; X = CH, N) were prepared by reaction of thienopyrazoles II with 1,3-dielectrophiles, such as acetylacetone, dibenzoylmethane, or 1,2,4-dithiazole. Another synthetic route for the preparation of the tricyclic systems, based on pyrazoloazines, was investigated. I and II (R = CO₂Me, CPh) exhibited antiulcer activity.

IT 139299-16-4P 139299-18-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and antiulcer activity of thienopyrazolopyrimidines and -triazines)

RN 139299-16-4 CAPLUS


CN Methanone, (3,4-diamino-1H-thieno[2,3-c]pyrazol-5-yl)phenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 139299-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:777293 CAPLUS Full-text

DOCUMENT NUMBER: 123:340045

ORIGINAL REFERENCE NO.: 123:61027a, 61030a

TITLE: Aminothieno[2,3-c]pyrazoles and aminothieno[2,3-b]pyrroles

AUTHOR(S): Gewald, K.; Rennert, S.; Schindler, R.; Schaefer, H.

CORPORATE SOURCE: Inst. Organische Chem., Technischen Univ., Dresden, Germany

SOURCE: Journal fuer Praktische Chemie/Chemiker-Zeitung (1995), 337(6), 472-7

CODEN: JPCCEM; ISSN: 0941-1216

PUBLISHER: Barth

DOCUMENT TYPE: Journal

LANGUAGE: German

AB The synthesis of thieno[2,3-c]pyrazolamines and thieno[2,3-b]pyrrolamines was described. These compds. were prepared from 3-amino-4-cyano-5- (methylthio)-1,2-dithiol-1-ium iodide as starting material.


IT 170953-43-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thieno[2,3-c]pyrazolamines and thieno[2,3-b]pyrrolamines)

RN 170953-43-2 CAPLUS

CN Methanone, (3,4-diamino-1H-thieno[2,3-c]pyrazol-5-yl)phenyl- (CA INDEX NAME)




IT 170953-44-3P 170953-45-4P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of thieno[2,3-c]pyrazolamines and thieno[2,3-b]pyrrolamines)

RN 170953-44-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carbonitrile, 3,4-diamino- (CA INDEX NAME)




RN 170953-45-4 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3,4-diamino- (CA INDEX NAME)



L3 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1992:106287 CAPLUS Full-text
 DOCUMENT NUMBER: 116:106287
 ORIGINAL REFERENCE NO.: 116:18003a,18006a
 TITLE: Preparation of thieno[2,3-c]pyrazole-3,4-diamines
 INVENTOR(S): Briel, Detlef; Moschke, Thomas; Wagner, Guenther;
 Lohmann, Dieter; Hoffmann, Wolfgang; Ploen, Ursula
 PATENT ASSIGNEE(S): Karl-Marx-Universitaet Leipzig, Germany
 SOURCE: Ger. (East), 6 pp.
 CODEN: GEXXA8
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 294485	A5	19911002	DD 1990-340708	19900516
PRIORITY APPLN. INFO.:			DD 1990-340708	19900516
OTHER SOURCE(S):	CASREACT 116:106287; MARPAT 116:106287			

GI




AB Title compds. I (R = H, Me; R1 = CO2Me, CO2Et, Bz) were prepared by treating thiophenes II (R2 = alkylsulfonyl) with RNHNH2 with or without isolation of the intermediates II (R2 = NRNH2). Thus, II (R1 = Bz, R2 = MeSO2) was prepared from II (R2 = SH) by methylation and oxidation and was treated with MeNHNH2 in MeOH under reflux followed by HCl-MeOH to give 60% I.HCl (R = Me, R1 = Bz).

IT 139299-16-4P 139299-18-6P 139299-19-7P
 139299-20-0P 139299-25-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 139299-16-4 CAPLUS
 CN Methanone, (3,4-diamino-1H-thieno[2,3-c]pyrazol-5-yl)phenyl-,
 hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 139299-18-6 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester,
 hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 139299-19-7 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester
 (CA INDEX NAME)



RN 139299-20-0 CAPLUS
 CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester,
 sulfate (2:1) (CA INDEX NAME)


CM 1

CRN 139299-19-7
CMF C7 H8 N4 O2 S




CM 2

CRN 7664-93-9
CMF H2 O4 S




RN 139299-25-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, ethyl ester,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:4942 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 106:4942
ORIGINAL REFERENCE NO.: 106:927a,930a
TITLE: Nitriles in heterocyclic synthesis. A novel synthesis
of 4-phenacylpyrazole and pyrrolo[2,3-c]pyrazole
derivatives
AUTHOR(S): Abdelrazek, Fathy Mohamed; Erian, Ayman Wahba; Hilmy,
Khalid Mohamed Hassan
CORPORATE SOURCE: Fac. Sci., Cairo Univ., Giza, Egypt
SOURCE: Synthesis (1986), (1), 74-5
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal

LANGUAGE: English
OTHER SOURCE(S): CASREACT 106:4942
GI




AB PhCOCH₂CH(CN)₂, prepared from PhCOCH₂Br and CH₂(CN)₂, underwent cyclization with RNHNH₂ (R = H, Ph) to give pyrazoles I, which were treated with Cl₃CCN to give pyrrolopyrazoles II.

IT 105576-69-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 105576-69-0 CAPLUS

CN Methanone, (3,5-diamino-1,6-dihydropyrrolo[2,3-c]pyrazol-4-yl)phenyl- (CA
INDEX NAME)



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 15:06:32 ON 22 AUG 2008